Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Despite significant medical advances, HF remains a chronic and progressive condition that can negatively affect patients’ quality of life (QoL).2,3 In this case study, Dr Abdul Muizz shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following the percutaneous coronary intervention, showing how the initiation of sacubitril/valsartan therapy (an angiotensin receptor/neprilysin inhibitor [ARNI]) changed the clinical outcome of this patient.
Janus kinase inhibitors (JAKIs) have emerged as an effective class of therapy for rheumatoid arthritis (RA).1 At the EULAR virtual symposium, a group of specialists discussed recent updates on tofacitinib (Xeljanz®, Pfizer) – the first-in-class JAKI for the treatment of RA.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.
As the COVID-19 pandemic continues to spread around the globe, comparison is often drawn to influenza, another contagious respiratory-borne disease. Recently, Dr Azureen Azmel, a consultant infectious disease physician at Hospital Tengku Ampuan Rahimah (HTAR), and Dr Leong Chee Loon, a consultant infectious disease physician with Hospital Kuala Lumpur (HKL), came together to discuss about the importance of annual influenza vaccination during the current COVID-19 pandemic.
An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Antihistamines (AHs) are the mainstay of treatment for allergic rhinitis (AR) in primary care. Nevertheless, choosing the best therapy from a wide selection of AHs can be challenging. At a virtual forum hosted by Bayer Co. (Malaysia), two experts discussed the role of patient profiling as a tool to guide the choice of AHs for AR.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.